Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(23)
•••
Post by thisisriskystufon Dec 27, 2018 10:52am
255 Views
Post# 29159663

Theratechnologies Stock Forecast, "THERF" Share Price Predic

Theratechnologies Stock Forecast, "THERF" Share Price PredicHistorical index on US Stock Market: B+ "Should I invest in Theratechnologies stock?" "Should I trade "THERF" stock today?" According to our live Forecast System, Theratechnologies Inc stock is an awesome long-term (1-year) investment*. "THERF" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "THERF" projections. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Theratechnologies Inc (THERF). If you are looking for stocks with good return, Theratechnologies Inc can be a profitable investment option. Theratechnologies Inc quote is equal to 5.740 USD at 2018-12-27. Based on our forecasts, a long-term increase is expected, the "THERF" stock price prognosis for 2023-12-20 is 18.713 USD. With a 5-year investment, the revenue is expected to be around +226.01%. Your current $100 investment may be up to $326.01 in 2023.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities